Association of finerenone plus tripterygium glycosides with proteinuria reduction in patients with diabetic kidney disease: a retrospective cohort study
Frontiers in Pharmacology · 02.11.2026 · 17
DOI: 10.3389/fphar.2026.2005388 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.11.2026. Verfasst von Qi Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Wuhan Fourth Hospital, Wuhan Clinical Research Center for Metabolic Chronic Kidney Disease, Wuhan, Hubei, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
We aimed to investigate the association of combined finerenone and tripterygium glycosides (TG) therapy with proteinuria reduction in patients with diabetic kidney disease (DKD).
Methods
This retrospective cohort study included patients with DKD and an estimated glomerular filtration rate (eGFR) of 15 to <60 mL/min/1.73 m 2 who received finerenone alone (n = 167) or finerenone plus TG (n = 36) during January, 2023–April 2026. Longitudinal urinary albumin-to-creatinine ratio (UACR) was evaluated using adjusted linear mixed-effects models. Multiple subgroup and sensitivity analyses were performed to assess the robustness of the findings. Associations between treatment groups and adverse events, including hyperkalemia, elevated liver transaminases, and a ≥1.5-fold increase in serum creatinine, were also evaluated.
Results
Among the 203 patients, the mean age was 65.1 years, the median UACR was 872.6 [273.8, 1723.1] mg/g, and the median eGFR was 46.2 [36.4, 53.3] mL/min/1.73 m 2 . Relative to finerenone alone, combination therapy was associated with an additional UACR reduction of 14.7% per 6 months (95% confidence interval [CI], [5.6%, 22.8%]; P = 0.002), equivalent to 27.5% per year (95% CI, [11.1%, 40.9%]). Combination therapy was associated with a higher rate of achieving a ≥50% reduction in UACR than finerenone alone (adjusted hazard ratio [HR], 2.02; 95% CI, 1.17–3.48; P = 0.011). During follow-up, serum potassium increased to a greater extent in the combination therapy group (P = 0.031), whereas longitudinal changes in serum creatinine and eGFR did not differ significantly between the groups (both P > 0.05). However, the incidences of hyperkalemia and liver and kidney-related adverse events were also comparable between the groups (all P > 0.05).
Conclusion
In patients with DKD and an eGFR of 15 to <60 mL/min/1.73 m 2 , combination therapy with TG and finerenone was associated with a greater reduction in UACR than finerenone alone, without a significant increase in the risk of the assessed adverse events. Further evaluation in prospective randomized trials is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Wuhan Fourth Hospital, Wuhan Clinical Research Center for Metabolic Chronic Kidney Disease, Wuhan, Hubei, China.
- Department of Information Technology, Wuhan Fourth Hospital, Wuhan Clinical Research Center for Metabolic Chronic Kidney Disease, Wuhan, Hubei, China.
Zitieren
APA
Gao, Q., Cai, Y., Zhang, Y., Song, X., Dong, J., Wei, H., Tian, M., & Su, K. (2026). Association of finerenone plus tripterygium glycosides with proteinuria reduction in patients with diabetic kidney disease: a retrospective cohort study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2005388
Vancouver
Gao Q, Cai Y, Zhang Y, Song X, Dong J, Wei H, et al. Association of finerenone plus tripterygium glycosides with proteinuria reduction in patients with diabetic kidney disease: a retrospective cohort study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2005388
BibTeX
@article{Gao2026,
author = {Gao, Qi and Cai, Yuan and Zhang, Yuanbo and Song, Xianci and Dong, Junwu and Wei, Honglan and Tian, Ming and Su, Ke},
title = {Association of finerenone plus tripterygium glycosides with proteinuria reduction in patients with diabetic kidney disease: a retrospective cohort study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2005388}
}
EUVIMED